Theradaptive

We are very excited to share a momentous achievement for Theradaptive: FDA approval to commence human clinical studies. Our journey advances with the initiation of the OASIS study, a groundbreaking Phase I/II examination of the safety and efficacy of OsteoAdapt in TLIF spinal fusion procedures.

This signifies that the remarkable product our team has dedicated extensive time and effort to is now poised for its inaugural use in treating humans. Together, we're staying true to our commitment to bring renewed hope to patients facing limited options.



https://www.prnewswire.com/news-releases/us-fda-grants-theradaptive-ide-approval-for-phase-iii-clinical-trials-302050556.html?tc=eml_cleartime